BD (NYSE: BDX) announced it received CE marking for its Liverty TIPS Stent Graft, allowing the device to be marketed across the European Union for treating portal hypertension complications in patients with cirrhosis.

The adjustable-diameter device features a 6-10 mm inner diameter range and is designed for transjugular intrahepatic portosystemic shunt procedures. The device includes a self-expanding nitinol frame with dual-layer ePTFE encapsulation and carbon impregnation on the inner surface.

"With CE Marking of the Liverty TIPS Stent Graft, we're introducing an innovative, adjustable solution that helps physicians personalize therapy and improve the potential for long-term outcomes," said Rima Alameddine, worldwide president of Peripheral Intervention at BD.

BD stated that safety and effectiveness data from the ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Scientific Meeting on April 12, 2026. The ARCH study was described as a global, prospective, multi-center, single-arm clinical study.

Portal hypertension can result from cirrhosis and lead to complications including variceal bleeding and fluid accumulation. According to the Global Burden of Disease study cited by BD, an estimated 58 million people worldwide live with cirrhosis.

The device remains investigational in the United States and is limited to investigational use only under U.S. law, the company stated.

Information is based on a BD press release statement.